tbuckley/cabot-search huggingface dataset:
Differences in Regional Brain Responses to Food Ingestion After Roux-en-Y Gastric Bypass and the Role of Gut Peptides: A Neuroimaging Study
Authors: Katharine F. Hunt, Joel T. Dunn, Carel W. le Roux, Laurence J. Reed, Paul K. Marsden, Ameet G. Patel, Stephanie A. Amiel
Journal: Diabetes Care (2016)

Improved appetite control, possibly mediated by exaggerated gut peptide responses to eating, may contribute to weight loss after Roux-en-Y gastric bypass (RYGB). This study compared brain responses to food ingestion between post-RYGB (RYGB), normal weight (NW), and obese (Ob) unoperated subjects and explored the role of gut peptide responses in RYGB.Neuroimaging with [(18)F]-fluorodeoxyglucose (FDG) positron emission tomography was performed in 12 NW, 21 Ob, and 9 RYGB (18 ± 13 months postsurgery) subjects after an overnight fast, once FED (400 kcal mixed meal), and once FASTED, in random order. RYGB subjects repeated the studies with somatostatin infusion and basal insulin replacement. Fullness, sickness, and postscan ad libitum meal consumption were measured. Regional brain FDG uptake was compared using statistical parametric mapping.RYGB subjects had higher overall fullness and food-induced sickness and lower ad libitum consumption. Brain responses to eating differed in the hypothalamus and pituitary (exaggerated activation in RYGB), left medial orbital cortex (OC) (activation in RYGB, deactivation in NW), right dorsolateral frontal cortex (deactivation in RYGB and NW, absent in Ob), and regions mapping to the default mode network (exaggerated deactivation in RYGB). Somatostatin in RYGB reduced postprandial gut peptide responses, sickness, and medial OC activation.RYGB induces weight loss by augmenting normal brain responses to eating in energy balance regions, restoring lost inhibitory control, and altering hedonic responses. Altered postprandial gut peptide responses primarily mediate changes in food-induced sickness and OC responses, likely to associate with food avoidance.
The effects of yoga on urban underserved breast cancer patients.
Authors: Xuan Luu, Kenneth Rifkind, Shubhada Dhage, Monti Castaneda, Xin Zeng, Kathie-Ann P. Joseph
Journal: Journal of Clinical Oncology (2014)

e17557 Background: The Office of Cancer Complementary and Alternative Medicine within the NCI posits that complementary/alternative medicine offers promise for QoL and treatment-related adverse effects. Given that ethnic minorities and underserved breast cancer survivors may be at greater risk for QoL impairment than white cancer survivors, we have designed a yoga study to address the needs of this target audience. Methods: This study used a randomized waitlist control design with QoL examined at two assessment points: T1 (baseline) and T2 (12 weeks). Patients were asked to complete the FACT-B and FACIT-Sp questionnaires. Patients were then randomized to the treatment group (one hour yoga classes) or control group. Both groups completed the questionnaires at the completion of the study. Results: 14 women were recruited to the control group and 24 women to the study group. The average age of the control group was 45, and 55 for the study group. The average FACIT-Sp score for the control group pre-treatment was 88.75; post-treatment, 90 . For the study group, the mean scores were 93.6 and 123.4. There was a significant increase in scores in the study group (p=0.004) while the increase in the control group was not significant. Moreover, there was a significant difference in the FACIT-Sp scores between the study and control groups at the termination of the study (p=0.001) whereas there was no difference in FACIT-Sp scores pre-treatment (NS). The mean FACT-B score for the control group pre-treatment was 70.5 and post-treatment 73.5. For the study group, the mean scores were 73.9 and 97.0. There was a significant increase in FACT-B scores in the study group (p=0.0009) while the increase in scores in the control group was not significant. Moreover, there was a significant difference in the scores between the study and control groups at the termination of the study (p=0.002) whereas there was no difference in the scores pre-treatment (NS). Conclusions: Hatha yoga can be a viable method of addressing QoL outcomes in an urban underserved population. Participation in yoga resulted in improved spiritual, emotional and physical well being compared to the control group.
Fibroscan and MRI Have Complementary Prognostic Values in Primary Sclerosing Cholangitis
Authors: C. Corpechot, S. Lemoinne, A. Ruiz, A. Kemkang, F. Gaouar, Y. Chrétien, C. Housset, L. Arrivé, O. Chazouillères
Journal: Journal of Hepatology (2016)
In Vivo Methylome Changes in Purified Peripheral Blood Blasts and T Cells of AML Patients Treated with Decitabine: Statistical Modelling of a Hypomethylation Response
Authors: Nadja Blagitko-Dorfs, Pascal Schlosser, Rainer Claus, Tobias Ma, Katharina Götze, Michael Heuser, Gerhard Heil, Sven Wessendorf, Andreas Neubauer, Jürgen Krauter, Irmgard Dresel, Konstanze Döhner, Gesine Bug, Hans Walter Lindemann, Helmut R. Salih, Sebastian Scholl, Carsten Mueller-Tidow, Wolfram Brugger, Olga Grishina, Björn Hackanson, Martin Schumacher, Michael Lübbert
Journal: Blood (2014)
Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms
Authors: Rupa Narayan, Jonathan Benjamin, Ginna Laport, Lu Tian, Keri Tate, Linda Elder, Leah Galvez, Randall Armstrong, Kevin Sheehan, Robert Lowsky, Sally Arai, Laura Johnston, David Miklos, Lori S. Muffly, Andrew R. Rezvani, Judith Shizuru, Wen-Kai Weng, Samuel Strober, Robert Negrin, Everett Meyer
Journal: Blood (2015)
Clinical and Social Psychological Profiles of Patients with Chronic Hepatitis C Treated with IFN-Free Regimens in France
Authors: S. Cossais, M. Schwarzinger, S. Pol, H. Fontaine, D. Larrey, G.-P. Pageaux, V. Canva, P. Mathurin, Y. Yazdanpanah, S. Deuffic- Burban
Journal: Journal of Hepatology (2016)
Analysis of Hemodynamic Effects of Bosentan on Portopulmonary Hypertension in Short-Term and Medium-Term Follow-Up: Promising Predictors of Response to Therapy?
Authors: A. Risso, W.G. Marra, S. Martini, F. Orzan, M.T. Cerenzia, F. Balzola, D. Arese, M. Sacco, S. Strona, D. Stradella, D. Libertucci, P.L. Omedè, A. Bissolino, D. Zema, G.M. Saracco, M. Rizzetto, A. Ottobrelli
Journal: Journal of Hepatology (2016)
Tumor treating fields: a novel treatment modality and its use in brain tumors
Authors: Andreas F Hottinger, Patricia Pacheco, Roger Stupp
Journal: Neuro-Oncology (2016)

Tumor treating fields (TTFields) are low-intensity electric fields alternating at an intermediate frequency (200kHz), which have been demonstrated to block cell division and interfere with organelle assembly. This novel treatment modality has shown promise in a variety of tumor types. It has been evaluated in randomized phase 3 trials in glioblastoma (GBM) and demonstrated to prolong progression-free survival (PFS) and overall survival (OS) when administered together with standard maintenance temozolomide (TMZ) chemotherapy in patients with newly diagnosed GBM. TTFields are continuously delivered by 4 transducer arrays consisting each of 9 insulated electrodes that are placed on the patient’s shaved scalp and connected to a portable device. Here we summarize the preclinical data and mechanism of action, the available clinical data, and further outlook of this treatment modality in brain tumors and other cancer indications.
The Insulin-Like Growth Factor 2 MRNA Binding Protein P62 Induces Liver Progenitor Cell Occurence
Authors: S.M. Kessler, B. Czepukojc, A. Barghash, C. Cadenas, J.G. Hengstler, V. Helms, I. Leclercq, J. Haybaeck, A.K. Kiemer
Journal: Journal of Hepatology (2016)
Does chemotherapy schedule matter when combining with bevacizumab? A stratified meta-analysis of randomized controlled trials.
Authors: Twan Ying Chang, Yaa Hui Dong, Ching-Hung Lin, Hsien Ho Lin, Sung Hsin Kuo, Chiu-Lin Lai, Mei-Shu Lai, Yen-Shen Lu
Journal: Journal of Clinical Oncology (2014)

1076 Background: Adding bevacizumab (Bev) to chemotherapy (CT) improved the objective response rate and progression free survival (PFS) in many randomized controlled trials (RCTs), but the magnitude of benefit varied. For example, in advanced breast cancer, the magnitude of prolongation of PFS in weekly chemotherapy study (E2100) was more significant than that in non-weekly chemotherapy studies (AVADO and RIBBON-1). We conducted a meta-analysis to examine the association of chemotherapy schedules with Bev benefit in advanced cancers. Methods: Through literature search, we identified 26 RCTs which compared combination of Bev plus CT with CT alone for advanced cancers. Among them, 21 RCTs which contained different CT schedules within certain cancer type were enrolled. These included 5, 4, 5 and 7 RCTs for breast, ovary, lung and colorectal cancers. A meta-analysis with random effects model was conducted to generate summary estimates of Bev benefit in terms of the improvement of PFS. CT schedules were classified into weekly (w), non-weekly (non-w), and weekly + non-weekly (w/non-w). We performed the stratified analysis of CT schedules, CT drugs, and CT lines, cancer types, and Bev dosage/schedule. The Bucher's method was used to indirectly compare the PFS improvement from Bev. Results: Among the 21 RCTs, 7, 12, and 2 studies were with w, non-w, and w/non-w CT schedules, respectively. Overall, Bev in combination with CT was associated with a significant benefit of PFS (hazard ratio [HR], 0.66; 95% CI, 0.60-0.73). The HRs for w, non-w, and w/non-w CT schedules were 0.53 (95% CI: 0.45-0.63), 0.74 (95%CI: 0.68-0.81), and 0.61 (95% CI: 0.40-0.93), respectively. Using Bucher's method, the benefit of adding Bev was significantly greater in w CT schedule than that in the non-w CT schedule (HR: 0.71; 95% CI: 0.59-0.87). In contrast, the benefit of adding Bev did not statistically differ among various CT drugs, CT lines, cancer types, or Bev dosage/schedule. The overall heterogeneity (I2=76.1% for 21 RCTs) was reduced after CT schedule stratification (I2=36.7% for w and I2=52.1% for non-w CT schedule). Conclusions: When combining Bev with CT, weekly CT schedule was associated with greater improvement of PFS.
Use of “high flow” Totally Implantable Central Venous Access Ports for Myeloablative Conditioning Followed by Allogeneic Stem Cell Transplantation: a Prospective Study.
Authors: Abderrahman Abdelkefi, Olfa Ben Gaied, Saloua Ladeb, Lamia Torjman, Amel Lakhal, Tarek Ben Othman
Journal: Blood (2009)
Management of Hepatic Epithelioid Haemangioendothelioma: 5 Year Single-Center Experience
Authors: R.C. Cerban, A. Croitoru, I. Popescu, S. Iacob, C. Pietrareanu, V. Herlea, F. Botea, G. Becheanu, R. Dumitru, C. Gheorghe, I. Lupescu, L. Gheorghe
Journal: Journal of Hepatology (2016)
Predictors of Improvement in NAFLD Activity Score on Placebo: A Secondary Analysis of the Flint Trial
Authors: R. Loomba, A.J. Sanyal, K.V. Kowdley, N. Terrault, N.P. Chalasani, M.F. Abdelmalek, A.J. McCullough, B. Ferguson, L. Lee, R. Shringarpure, D. Shapiro, B.A. Neuschwander-Tetri
Journal: Journal of Hepatology (2016)
Chronic Kidney Disease in Primary Care: Outcomes after Five Years in a Prospective Cohort Study
Authors: Adam Shardlow, Natasha J. McIntyre, Richard J. Fluck, Christopher W. McIntyre, Maarten W. Taal
Journal: PLoS Medicine (2016)

Chronic kidney disease (CKD) is commonly managed in primary care, but most guidelines have a secondary care perspective emphasizing the risk of end-stage kidney disease (ESKD) and need for renal replacement therapy. In this prospective cohort study, we sought to study in detail the natural history of CKD in primary care to better inform the appropriate emphasis for future guidance.In this study, 1,741 people with CKD stage 3 were individually recruited from 32 primary care practices in Derbyshire, United Kingdom. Study visits were undertaken at baseline, year 1, and year 5. Binomial logistic regression and Cox proportional hazards models were used to model progression, CKD remission, and all-cause mortality. We used Kidney Disease: Improving Global Outcomes (KDIGO) criteria to define CKD progression and defined CKD remission as the absence of diagnostic criteria (estimated glomerular filtration rate [eGFR] >60 ml/min/1.73 m2 and urine albumin-to-creatinine ratio [uACR] <3 mg/mmol) at any study visit. Participants were predominantly elderly (mean ± standard deviation (SD) age 72.9 ± 9.0 y), with relatively mild reduction in GFR (mean ± SD eGFR 53.5 ± 11.8 mL/min/1,73 m2) and a low prevalence of albuminuria (16.9%). After 5 y, 247 participants (14.2%) had died, most of cardiovascular causes. Only 4 (0.2%) developed ESKD, but 308 (17.7%) evidenced CKD progression by KDIGO criteria. Stable CKD was observed in 593 participants (34.1%), and 336 (19.3%) met the criteria for remission. Remission at baseline and year 1 was associated with a high likelihood of remission at year 5 (odds ratio [OR] = 23.6, 95% CI 16.5-33.9 relative to participants with no remission at baseline and year 1 study visits). Multivariable analyses confirmed eGFR and albuminuria as key risk factors for predicting adverse as well as positive outcomes. Limitations of this study include reliance on GFR estimated using the Modification of Diet in Renal Disease study (MDRD) equation for recruitment (but not subsequent analysis) and a study population that was predominantly elderly and white, implying that the results may not be directly applicable to younger populations of more diverse ethnicity.Management of CKD in primary care should focus principally on identifying the minority of people at high risk of adverse outcomes, to allow intervention to slow CKD progression and reduce cardiovascular events. Efforts should also be made to identify and reassure the majority who are at low risk of progression to ESKD. Consideration should be given to adopting an age-calibrated definition of CKD to avoid labelling a large group of people with age-related decline in GFR and low associated risk as having CKD.
Ultra high risk status and transition to psychosis in 22q11.2 deletion syndrome
Authors: Maude Schneider, Marco Armando, Maria Pontillo, Stefano Vicari, Martin Debbané, Frauke Schultze‐Lutter, Stephan Eliez
Journal: World Psychiatry (2016)

The 22q11.2 deletion syndrome (22q11DS) is characterized by high rates of psychotic symptoms and schizophrenia, making this condition a promising human model for studying risk factors for psychosis. We explored the predictive value of ultra high risk (UHR) criteria in a sample of patients with 22q11DS. We also examined the additional contribution of socio-demographic, clinical and cognitive variables to predict transition to psychosis within a mean interval of 32.5 ± 17.6 months after initial assessment. Eighty-nine participants with 22q11DS (age range: 8-30 years; mean 16.1 ± 4.7) were assessed using the Structured Interview for Psychosis-Risk Syndromes. Information on Axis I diagnoses, internalizing and externalizing symptoms, level of functioning and IQ was also collected. At baseline, 22 (24.7%) participants met UHR criteria. Compared to those without a UHR condition, they had a significantly lower functioning, more frequent anxiety disorders, and more severe psychopathology. Transition rate to psychosis was 27.3% in UHR and 4.5% in non-UHR participants. Cox regression analyses revealed that UHR status significantly predicted conversion to psychosis. Baseline level of functioning was the only other additional predictor. This is the first study investigating the predictive value of UHR criteria in 22q11DS. It indicates that the clinical path leading to psychosis is broadly comparable to that observed in other clinical high-risk samples. Nevertheless, the relatively high transition rate in non-UHR individuals suggests that other risk markers should be explored in this population. The role of low functioning as a predictor of transition to psychosis should also be investigated more in depth.
Role of Toll-Like Receptor 4 in Modulating the Brain-Gut Axis in the Pathogenesis of Hepatic Encephalopathy
Authors: Y. Sharifi, N. Arias, G. Wright, N. Shah, M. Oria, D. Adebayo, F. De Chiara, L. Chavarria, F. Scaravilli, R. Jalan
Journal: Journal of Hepatology (2016)
Robot-assisted Level II–III Inferior Vena Cava Tumor Thrombectomy: Step-by-Step Technique and 1-Year Outcomes
Authors: Sameer Chopra, Giuseppe Simone, Charles Metcalfe, Andre Luis de Castro Abreu, Jamal Nabhani, Mariaconsiglia Ferriero, Alfredo Maria Bove, Rene Sotelo, Monish Aron, Mihir M. Desai, Michele Gallucci, Inderbir S. Gill
Journal: European Urology (2016)
Secreted Frizzled-Related Protein-3 (sFRP3) Is Produced by Myeloma Cells and Augments Wnt3a-Induced Differentiation of Mesenchymal Stem Cells and OPG Production in Osteoblasts
Authors: Ya-Wei Qiang, Yu Chen, Bo Hu, Wei Qiang, Christoph Heuck, Shmuel Yaccoby, Joshua Epstein, Bart Barlogie, John D Shaughnessy
Journal: Blood (2011)
Clinical Study of Autologous Cytokine-Induced Killer Cells for the Consolidation Treatment of Elderly Patients with Diffuse Large B-Cell Lymphoma
Authors: Shenxian Qian, Pengfei Shi, Yaping Xie, Ying Xu, Daquan Gao, Lirong Liu, Xilian Huang, Kuang Chen, Junfeng Tan
Journal: Blood (2014)
Studying the Role of Financial Incentives to Promote Hepatitis B Vaccination in a Community Clinic
Authors: Benjamin S. Wilfond, Christian Morales, Holly A. Taylor
Journal: The American Journal of Bioethics (2016)

"Studying the Role of Financial Incentives to Promote Hepatitis B Vaccination in a Community Clinic." The American Journal of Bioethics, 16(10), pp. 75–76
Restoring the Expression of Endogenous IGF-1 by MIR-486 in NK Cells of HCC Patients Augments its Cytotolytic Activity against Hepatoma Cell Lines
Authors: R.A. Youness, M.A. Rahmoon, R.A. Assal, A.I. Gomaa, I. Waked, H.M. El Tayebi, A.I. Abdelaziz
Journal: Journal of Hepatology (2016)
Hepatitis C Diagnosis and Linkage to Care Rates in an Urban Emergency Department Blood Borne Virus Screening Programme
Authors: S. O’Connell, D. Lillis, A. Cotter, S. O’Dea, A. Moriarty, D. Shields, H. Tuite, B. Crowley, S. Norris, P.K. Plunkett, C. Bergin
Journal: Journal of Hepatology (2016)
Population-based health care cost estimates related to breast cancer by staging.
Authors: N. Mittmann, P. K. Isogai, R. Saskin, N. Liu, J. Hoch, N. B. Leighl, M. C. Cheung, M. E. Trudeau, W. K. Evans, K. Dainty, C. Earle
Journal: Journal of Clinical Oncology (2011)

6108 Background: This study provides population-based estimates of the costs for women with breast cancer (BC) by disease stage from a Canadian perspective using provincial administrative databases. Methods: All Ontario women with a diagnosis of first incident BC from the Ontario Cancer Registry (2005-2009) were matched to non-BC controls (1:5) based on age (same birth year), geography, income quintile, and the expected resource utilization bands (2 years prior to cancer diagnosis) were linked with their unique and encrypted Health Card Number to provincial health claims (Ontario Ministry of Health and Longterm Care and Cancer Care Ontario). Resources for this preliminary analysis included physician, hospitalizations and same day surgeries (SDS). Unit costs, 2009 Canadian dollars, were applied to resources. Non 2009 costs were inflated to 2009. The cost for BC vs. non-BC was calculated for the entire cohort and by stage of disease for BC cases. Results: There were 39,656 BC cases and 198,280 non-BC controls. Cases and controls were equally matched. The mean age (range) was 61.56 (51-72) years. 87.3% lived in urban areas. The total mean cost per person year (BC vs. non-BC) for physicians was $2,986 vs. $1,155; inpatient $2,972 vs. $1,015; SDS $470 vs. $147. Stage information was available for 15,437 (38.9%) BC cases, where 48.2% were stage I; 34.7% stage II; 10.3% stage III, 6.9% stage IV. Physician costs were $2,894 vs. $1,147 (stage I) for BC vs. non-BC; $3,312 vs. $1,133 (stage II); $4,027 vs. $1,036 (stage III); $5,459 vs. $1,092 (stage IV). Inpatient costs were $1,819 vs. $832 (stage I) for BC vs. non-BC; $3,010 vs. $866 (stage II); $4,774 vs. $816 (stage III); $12,123 vs. $1,009 (stage IV). SDS costs were $462 vs. $143 (stage I) for BC vs. non-BC; $468 vs. $129 (stage II); $455 vs. $124 (stage III); $336 vs. $137 (stage IV). Conclusions: This study provides stage-specific cost estimates for BC, where costs were 2-12 fold higher than those for non-BC and increased by stage for physician and inpatient resources. Further work will focus on costing other resources including medications, home care and radiation.
Reply from Authors re: Jens Uwe Stolzenburg, Iason Kyriazis, Evangelos Liatsikos. Postoperative Lymphocele Formation after Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy Should Not Be Considered an Inevitable Consequence of the Approach. Eur Urol 2017;71:159–60
Authors: Agostino Mattei, Pietro Grande, Giovanni Battista Di Pierro
Journal: European Urology (2016)
Is there a clinical evidence of an anti-tumoral effect of zoledronic acid in multiple myeloma patients post-autologous stem cell transplantation? Experience of the STAR (stem cell transplantation in the Antwerp region) group
Authors: Pierre Zachee, Maria De Samblanx, W Schroyens, S Van Steenweghen, A Van de Velde, A Gadisseur, E Steel, Z Berneman
Journal: Blood (2003)
Comment on "prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols" [5] (multiple letters)
Authors: Stefano Ferrari, Mario Mercuri, Gaetano Bacci, Stefan S. Bielack, Heribert JüRGENS
Journal: Journal of Clinical Oncology (2002)